MX2024000761A - Inhibidores peptidicos biciclicos del receptor de interleucina-23. - Google Patents
Inhibidores peptidicos biciclicos del receptor de interleucina-23.Info
- Publication number
- MX2024000761A MX2024000761A MX2024000761A MX2024000761A MX2024000761A MX 2024000761 A MX2024000761 A MX 2024000761A MX 2024000761 A MX2024000761 A MX 2024000761A MX 2024000761 A MX2024000761 A MX 2024000761A MX 2024000761 A MX2024000761 A MX 2024000761A
- Authority
- MX
- Mexico
- Prior art keywords
- interleukin
- receptor
- peptide inhibitors
- bicyclic peptide
- disorders
- Prior art date
Links
- 102100036672 Interleukin-23 receptor Human genes 0.000 title abstract 3
- 101710195550 Interleukin-23 receptor Proteins 0.000 title abstract 3
- 125000002619 bicyclic group Chemical group 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163221854P | 2021-07-14 | 2021-07-14 | |
| PCT/US2022/037202 WO2023288017A2 (en) | 2021-07-14 | 2022-07-14 | Bicyclic peptide inhibitors of interleukin-23 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000761A true MX2024000761A (es) | 2024-04-18 |
Family
ID=84920518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000761A MX2024000761A (es) | 2021-07-14 | 2022-07-14 | Inhibidores peptidicos biciclicos del receptor de interleucina-23. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240352073A1 (https=) |
| EP (1) | EP4370532A4 (https=) |
| JP (1) | JP2024525723A (https=) |
| KR (1) | KR20240034223A (https=) |
| CN (1) | CN117980320A (https=) |
| AR (1) | AR126457A1 (https=) |
| AU (1) | AU2022310347A1 (https=) |
| CA (1) | CA3226492A1 (https=) |
| MX (1) | MX2024000761A (https=) |
| TW (1) | TW202321275A (https=) |
| UY (1) | UY39858A (https=) |
| WO (1) | WO2023288017A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| HRP20211448T1 (hr) | 2014-05-16 | 2021-12-24 | Protagonist Therapeutics, Inc. | Alfa4beta7 integrin tioeter peptidni antagonisti |
| CN107206254B (zh) | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| AU2021209086A1 (en) | 2020-01-15 | 2022-08-04 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| JP7397239B2 (ja) | 2020-11-20 | 2023-12-12 | ヤンセン ファーマシューティカ エヌ．ベー． | インターロイキン－２３受容体のペプチド阻害剤の組成物 |
| EP4370146A4 (en) | 2021-07-14 | 2025-05-21 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of the interleukin-23 receptor |
| WO2024155551A1 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Polycyclic peptide inhibitors of interleukin-23 receptor |
| EP4471049A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| EP4471048A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| CN121909205A (zh) | 2023-09-08 | 2026-04-21 | 赛诺菲 | 作为选择性il-23受体抑制剂的新型肽 |
| CN121794283A (zh) | 2023-09-08 | 2026-04-03 | 赛诺菲 | 作为选择性il-23受体抑制剂的新型肽 |
| WO2025076414A1 (en) * | 2023-10-06 | 2025-04-10 | The Children's Medical Center Corporation | Compositions and methods for selecting a subject for inflammatory bowel disease treatment |
| WO2026013260A1 (en) | 2024-07-12 | 2026-01-15 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| WO2026041110A1 (zh) * | 2024-08-22 | 2026-02-26 | 上海瀚辰星泰医药科技有限公司 | 一种多肽化合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107206254B (zh) * | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| US10301371B2 (en) * | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
| MX384213B (es) * | 2015-07-15 | 2025-03-14 | Protagonist Therapeutics Inc | Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias. |
| JP7100034B2 (ja) * | 2016-12-06 | 2022-07-12 | シュティヒティング・ヴォール・デ・テクニシェ・ヴェテンシャッペン | 多環式ペプチド及びそれらの調製方法 |
| WO2019034866A1 (en) * | 2017-08-14 | 2019-02-21 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF |
| CN111712509A (zh) * | 2017-12-15 | 2020-09-25 | 詹森生物科技公司 | 作为sting激动剂的环状二核苷酸 |
| WO2020014646A1 (en) * | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| WO2021007433A1 (en) * | 2019-07-10 | 2021-01-14 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
-
2022
- 2022-07-14 EP EP22842895.9A patent/EP4370532A4/en active Pending
- 2022-07-14 CN CN202280062001.1A patent/CN117980320A/zh active Pending
- 2022-07-14 US US18/579,033 patent/US20240352073A1/en active Pending
- 2022-07-14 CA CA3226492A patent/CA3226492A1/en active Pending
- 2022-07-14 TW TW111126553A patent/TW202321275A/zh unknown
- 2022-07-14 MX MX2024000761A patent/MX2024000761A/es unknown
- 2022-07-14 WO PCT/US2022/037202 patent/WO2023288017A2/en not_active Ceased
- 2022-07-14 UY UY0001039858A patent/UY39858A/es unknown
- 2022-07-14 JP JP2024501737A patent/JP2024525723A/ja active Pending
- 2022-07-14 AR ARP220101855A patent/AR126457A1/es unknown
- 2022-07-14 AU AU2022310347A patent/AU2022310347A1/en active Pending
- 2022-07-14 KR KR1020247004796A patent/KR20240034223A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024525723A (ja) | 2024-07-12 |
| UY39858A (es) | 2023-02-28 |
| KR20240034223A (ko) | 2024-03-13 |
| CA3226492A1 (en) | 2023-01-19 |
| EP4370532A2 (en) | 2024-05-22 |
| WO2023288017A3 (en) | 2023-03-09 |
| WO2023288017A2 (en) | 2023-01-19 |
| TW202321275A (zh) | 2023-06-01 |
| US20240352073A1 (en) | 2024-10-24 |
| CN117980320A (zh) | 2024-05-03 |
| AU2022310347A1 (en) | 2024-02-29 |
| EP4370532A4 (en) | 2025-09-03 |
| AR126457A1 (es) | 2023-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000761A (es) | Inhibidores peptidicos biciclicos del receptor de interleucina-23. | |
| MX2024000760A (es) | Inhibidores peptídicos lipídicos del receptor de interleucina-23. | |
| CO2023007172A2 (es) | Composiciones de inhibidores peptídicos del receptor de interleucina-23 | |
| MX2024000762A (es) | Inhibidores peptidicos del receptor de interleucina-23. | |
| EP4613761A3 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| MX2022000397A (es) | Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. | |
| AR119389A1 (es) | Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias | |
| MX2021000925A (es) | Inhibidores de inflamasoma nlrp3. | |
| MX2020006459A (es) | Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. | |
| MX2023003348A (es) | Compuestos y composiciones como moduladores de señalización tlr. | |
| UY40135A (es) | Inhibidores peptídicos del receptor de interleucina-23 y composiciones farmacéuticas de estos | |
| SA522432749B1 (ar) | I/alk5 مشتقات بنزيلاميد كمستقبل لمثبطات عامل النمو المتحول-بيتا | |
| PH12021552358A1 (en) | Compounds and compositions as modulators of tlr signaling | |
| MX2023010661A (es) | Moléculas de union al receptor leucocitario humano similar a inmunoglobulina b1 (lilrb1) y al receptor leucocitario humano similar a inmunoglobulina b2 (lilrb2) y usos para las mismas. | |
| MX2025008274A (es) | Formulaciones de inhibidores peptidicos lipidados del receptor de interleucina-23 | |
| WO2024155547A3 (en) | Peptide inhibitors of interleukin-23 receptor | |
| MX2025008273A (es) | Inhibidores peptidicos del receptor de interleucina-23 | |
| PH12021551760A1 (en) | Amino acid derivatives for the treatment of inflammatory diseases | |
| DOP2025000151A (es) | Inhibidores peptídicos del receptor de interleucina-23 | |
| MX2025008922A (es) | Metodos para preparar inhibidores peptidicos cristalinos del receptor de interleucina-23 | |
| WO2022150167A3 (en) | Novel macrocyclic opioid peptides |